Xenon Pharmaceuticals

Xenon Pharmaceuticals is a clinical genetics-based drug discovery and development company engaged in developing novel small molecule therapeutics based on the genetic causes of select metabolic,neurological andcardiovascular diseases.

Xenon has distinguished itself in the world of genetics-based drug discovery by taking a clinically driven approach to the identification of novel targets and drugs. Xenon develops these novel drugs based upon druggable genes and proteins that have significant functional disease validation and are therefore highly relevant for drug development.

The Company'slead programs aretargetingnovel treatments for obesity,metabolic syndrome, neurological disorders and common disorders ofiron metabolism such as iron overload. Key unmet needs persist in the management of these disease areas, including the need for refined drug targets with increased pharmacological specificity. Therefore, a significant opportunity exists for the development of novel, effective drug therapies that address the shortfalls of currently available therapeutics.

Xenon's innovative approach to identifying quality, disease relevant drug targets increases the likelihood of improved drug efficacy and safety.

Through the Company's expertise in assay development, high throughput screening and in vivo pharmacology, Xenon is rapidly advancing its drug programs through small molecule lead optimization and pre-clinical development and expects to initiate clinical development by Q1, 2005 in its lead Obesity / Metabolic Syndrome program.

Over the longer term, Xenon plans to further forward integrate its capabilities to become a leading clinical genetics based pharmaceutical company, developing and in select cases, marketing its own therapeutics for human health.

Website:

http://www.xenon-pharma.com

Address:

3650 Gilmore Way, Burnaby
Vancouver, British Columbia, Canada V5G 4W8